Orca Biosystems, Inc.

Privately held: no public share price

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Orca-T(TREGZI)
Approved
Allogeneic engineered T-cell immunotherapyCell therapy
Acute Myeloid Leukemia
Phase 1/2
Treg-enriched allogeneic haematopoietic stem cell graftCell therapy
Acute Myeloid Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Orca-T · TREGZIPhase 2Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
Est. primary completion 2027-11 · NCT07216443 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 June 2026ApprovalOrca-TFDA approves TREGZI (Orca-T)
US, FDA · Orca Bio · Source ↗
6 October 2025Priority reviewOrca-TFDA accepts Orca-T BLA with priority review
US, FDA · Orca Bio · Source ↗
10 February 2025Topline resultOrca-TPrecision-T Phase 3 meets primary endpoint
Orca Bio · Source ↗

Financial reports

No financial reports recorded.